Gainers

• Pulsenmore (NASDAQ:PLSM) shares increased by 171.2% to $10.47 during Monday's pre-market session. The company's market cap stands at $25.1 million.
• Q32 Bio (NASDAQ:QTTB) stock rose 65.92% to $18.6. The market value of their outstanding shares is at $190.0 million.
• Agenus (NASDAQ:AGEN) shares rose 41.49% to $4.74. The company's market cap stands at $139.5 million.
• Basel Medical Group (NASDAQ:BMGL) shares increased by 10.52% to $7.3. The company's market cap stands at $10.3 million.
• Eikon Therapeutics (NASDAQ:EIKN) stock moved upwards by 9.54% to $11.59. The market value of their outstanding shares is at $572.7 million.
• Accuray (NASDAQ:ARAY) stock increased by 9.44% to $0.26. The market value of their outstanding shares is at $28.7 million.

Losers

• BNB Plus (NASDAQ:BNBX) stock decreased by 51.3% to $0.18 during Monday's pre-market session. The company's market cap stands at $2.7 million.
• ENvue Medical (NASDAQ:FEED) stock declined by 12.66% to $0.46. The market value of their outstanding shares is at $3.2 million.
• Scienture Holdings (NASDAQ:SCNX) stock decreased by 12.19% to $0.33. The market value of their outstanding shares is at $15.0 million.
• Bluejay Diagnostics (NASDAQ:BJDX) stock declined by 11.02% to $1.29. The company's market cap stands at $1.5 million.
• Innovative Eyewear (NASDAQ:LUCY) shares declined by 10.85% to $0.96. The market value of their outstanding shares is at $9.2 million.
• Nexalin Technology (NASDAQ:NXL) stock decreased by 8.82% to $0.42. The market value of their outstanding shares is at $9.9 million. See Also: www.benzinga.com/money/best-healthcare-stocks/

This article was generated by Benzinga's automated content engine and reviewed by an editor.

Disclaimer:This article represents the opinion of the author only. It does not represent the opinion of Webull, nor should it be viewed as an indication that Webull either agrees with or confirms the truthfulness or accuracy of the information. It should not be considered as investment advice from Webull or anyone else, nor should it be used as the basis of any investment decision.